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Abstract The human MDRl gene encodes the multidrug 
transporter P-glycoprotein (Pgp). Although the MDRZ/F’gp 
shares about 80% identity at the amino acid level with the 
MDRlIPgp, the MDR2/Pgp cannot act as a multidrug 
transporter. We examined the drug sensitivity of Saccharomyces 
cerevisiae expressing either the human MDRl/Pgp or MDR2l 
Pgp. The human MDRl/Pgp conferred about 4-fold resistance to 
aureohasidin A, a cyclic depsipeptide antifungal antibiotic, on the 
drug-sensitive yeast strains. Interestingly the human MDR21Pgp 
also conferred about 2.5-fold resistance to aureobasidin A. The 
resistance to aureobasidin A conferred by the MDR2/Pgp as well 
as by the MDRllPgp was overcome by vinblastine, verapamil, 
and cyclosporin A, depending on their concentrations, but not by 
colchicine. Aureobasidin A probably interacts directly with Pgps, 
because it overcame multidrug resistance of human cells and 
inhibited azidopine photoaffinity labeling of MDRl/Pgp in 
human cell membranes. These results suggest the possibility that 
the human MDRl and MDRZ/Pgps have conserved domain(s) 
for drug recognition. 
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1. Introduction 
Multidrug resistance (MDR) in cultured cells is caused by 
the overexpression of P-glycoprotein (Pgp) and hence Pgp is 
supposed to be involved in MDR in tumor cells. Pgps are 
encoded by a small gene family, which includes two members 
in humans, MDRl and MDR2, and three members in mice, 
mdrla, mdrlb, and mdr2. Overexpression of human MDRl, or 
mouse mdrla and mdrlb, in drug-sensitive cultured cells can 
confer multidrug resistance [l-3], while human MDR2 and 
mouse mdr2 cannot [4,5]. 
It has been proposed that the human MDRl/Pgp partici- 
pates in the protection of organs against toxic xenobiotics and 
in transport of some natural steroid hormones in adrenal and 
in placental trophoblasts [6,7]. The mouse mdr2/Pgp has been 
shown to be indispensable for the secretion of phospholipids 
into bile [8] and to function as a phosphatidylcholine-specific 
translocase [9]. The mouse mdrla or mdrlb/Pgp was unable 
to compensate for the function of the mdr2/Pgp [8]. These 
results suggest that the substrates and the physiological func- 
tions of the two types of Pgp are different. 
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Substrates for the human MDRllPgp include peptides such 
as valinomycin [lo], gramicidin D [l 11, cyclosporin A [12], a 
tripeptide N-acetyl-leucyl-leucyl-norleucinal [13], and yeast a- 
factor mating peptide [14]. During our search for peptide anti- 
biotics which interact with human Pgp, we found that Sac- 
charomyces cerevisiae expressing human MDRllPgp showed 
resistance to aureobasidin A, a new antifungal cyclic depsi- 
peptide antibiotic produced by Aureobasidium pullulans R106 
[15,16]. Surprisingly the overexpression of MDR2/Pgp also 
conferred resistance to aureobasidin A. The resistance to au- 
reobasidin A was overcome by vinblastine, verapamil, and 
cyclosporin A, depending on the concentrations, suggesting 
that two types of human Pgps have conserved domain(s) for 
drug recognition. 
2. Materials and methods 
2.1. Materials 
Monoclonal antibody C219 was purchased from Centocor. 
[3H]Azidopine (1850 GBq/mmol) was purchased from Amersham 
Corp. Aureobasidin A was kindly provided by Takara Shuzo Co., 
Ltd. 
2.2. Yeast strains 
S. cerevisiae W303-1A (MATa ura3-52 leu2-3,112 his3-11,115 trpl-I 
ade2-I canl-100) was kindly provided by Dr. Karl Kuchler. To isolate 
a drug-sensitive variant, W303-1A was treated with 5 mM ethyl 
methanesulfonate and was screened for resistance to 3 pg/ml nystatin. 
Several strains were tested for sensitivity to various drugs, and strain 
W303-lAY18 was isolated. Nystatin-resistant strains were reported to 
change the content of ergosterol in the membrane and hence to in- 
crease the sensitivity to various drugs [17]. However, the UV absorp- 
tion spectra of the nonsaponifiable lipid extracts of the nystatin-re- 
sistant strain W303-lAY18 showed the presence of ergosterol in the 
membrane similarly to the wild-type W303-1A (data not shown). The 
reason that W303-lAY18 is resistant to nystatin and moderately sen- 
sitive to various drugs is unknown. 
2.3. Plasmids and yeast transformation 
The multi-copy plasmid YEp is used for expression in yeast cells of 
the human wild-type MDRl gene [18] (pYM/MDRl) or the MDR2 
gene [19] (pYM/MDR2) from the glyceraldehyde 3-phosphate dehy- 
drogenase promoter. Yeast cells were transformed with pYMlMDR1 
or pYM/MDRZ by the lithium acetate method. The human MDR2 
gene [19] was obtained from the American Type Culture Collection. 
2.4. Drug resistance assays of yeast cells 
Drug resistance was at first tested with an agar plate assay by 
streaking the overnight yeast cultures (diluted to As95 = 1.0) on SD 
plates containing appropriate concentrations of drugs. Growth was 
monitored after incubation at 30°C for 3 days. Growth inhibition 
assays were done in flat-bottom 96-well microplates, with wells con- 
taining equal volumes (50 ~1) of YPD medium with or without au- 
reobasidin A. Yeast cells grown to stationary phase were diluted in 
YPD (Ass5 = 0.2). Equal volumes of these cultures (50 l,d) were added 
to each well and incubated at 30°C for 24 h. Growth was measured 
optically at 595 nm on a microplate reader after incubation at 30°C 
for 24 h. 
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3. Results and discussion 
We introduced human MDRI and MDR2 expression vec- 
tors into a drug-sensitive yeast strain W303-lAY18. Each 
transformant was examined to possess appropriate plasmids 
by PCR with MDRl- or MDR2-specific primers (data not 
shown). The membrane fractions were prepared from the 
transformants and analyzed by immunoblotting for the pres- 
ence of the human MDRl and MDRuPgps using monoclonal 
antibody C219 which recognizes both Pgps (Fig. 1). The mem- 
brane fraction from transformants showed a unique immu- 
noreactive band with an apparent molecular mass of 140 
kDa, which was absent from the membrane fraction from 
the control cells. Human MDR2/Pgp (1279 aa) migrated at 
approximately the same position as MDRl/gp (1280 aa). The 
apparent low molecular mass compared to those expressed in 
human cells was probably caused by the lack of glycosylation 
[14,20,21]. 
The colony formation assay was first used to assess func- 
tionality of human MDRl and MDR2/F$ps expressed in 
drug-sensitive yeast strains, and the resistance to aureobasidin 
A, a new cyclic depsipeptide antifungal antibiotic, of those 
expressing the human MDRllPgp was noticeable (Fig. 2A). 
The human MDRI transformants formed colonies on plates 
containing 0.15 pg/ml aureobasidin A, while yeasts harboring 
the control vector did not. Surprisingly the human MDR2 
transformants also showed resistance to 0.1 Fg/ml aureobasi- 
din A (Fig. 2C). 
The effects of aureobasidin A on cell growth were then 
examined in liquid cultures (Fig. 3). When growth rates at 
given aureobasidin A concentrations relative to growth in its 
absence were plotted as a function of aureobasidin A concen- 
tration, the I&s (concentrations required for inhibiting the 
growth rate by 50%) for W303-lAY18IMDRl and W303- 
lAYlUMDR2 were 3.7 and 2.5 times higher than that for 
cells harboring the control vector, respectively. 
We examined the possibility of direct interaction of aureo- 
basidin A with the human MDRl/Pgp using the human MDR 
cultured cells KB-G2 [lo], which were obtained by introdu- 
cing the MDRI expression vector into drug-sensitive KB3-1 
cells and had a typical MDR phenotype. In the presence of 2 
pM aureobasidin A, the concentrations of vinblastine (Fig. 
4A) and colchicine (data not shown) inhibiting the growth 
rate of KB-G2 by 50% were shifted as low as that for the 
drug-sensitive KB-3-1 cells. Furthermore aureobasidin A in- 
hibited photoaffinity labeling with [3H]azidopine of MDRlI 
Pgp in the membrane fraction prepared from KB-G2 (Fig. 
4B). These results suggest that aureobasidin A interacts di- 
Fig. 1. Immunoblotting of membrane fraction from S. cerevisiae 
W303-lAY18/vector (lane I), W303-lAY18/MDRl (lane 2), W303- 
lAYlUMDR2 (lane 3) and human MDR cultured cells KB-G2 [lo] 
(lane 4). 20 pg of membrane protein was put on each lane, and was 
reacted with monoclonal antibody C219 as a probe for P-glycopro- 
tein. Molecular size standards are indicated in kDa on the right. 
MDRl Vector MDR2 Vector 
Fig. 2. Resistance of S. cerevisiae W303-lAY18 harboring human 
MDRl or MDR2 expression vector. Overnight cultures of W303- 
lAY18 harboring the control vector, pYM/MDRI or pYMIMDR2 
were diluted to Ass5 = 1.0 by media and streaked on SD plates con- 
taining 0 (B and D), 0.1 (C), or 0.15 Kg/ml aureobasidin A (A). The 
plates were incubated at 30°C for 3 days. 
rectly with the human MDRllPgp and competes with vinblas- 
tine, colchicine, and azidopine at common drug binding 
site(s). 
Because aureobasidin A has low toxicity for cultured cells 
and because we could not obtain an isotope-labeled aureoba- 
sidin A with a high specific activity, we could not examine if 
the human MDRl and MDR2/Pgps would transport it. But if 
this is the case, substrates for the human MDRl/Pgp such as 
verapamil, cyclosporin A and vinblastine which have high 
affinity to the human MDRl/Pgp would be expected to de- 
press the aureobasidin A resistance of yeast cells conferred by 
the human MDRlIPgp. 
The resistance to aureobasidin A conferred by MDRl/Pgp 
was overcome by vinblastine, verapamil, and cyclosporin A 
depending on the concentrations (Fig. 5A). Especially in the 
presence of cyclosporin A at a concentration of 5 PM, which 
is expected to be an efficient MDR modulator because of its 
high modulating activity [22], W303-1AY 18/MDRl became as 
sensitive as the control yeast cells. Colchicine, which is also a 
substrate for the human MDRl/Pgp but has low affinity to 
the human MDRl/Pgp [23], did not have any effect. These 
results suggest that in the plasma membrane of yeast strain 
W303-lAY18 the MDRUPgp retains functional drug binding 
site(s) with a substrate specificity similar to that formed in the 
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Fig. 3. A: Growth inhibition assay of W303-lAY18 harboring the 
control vector (o), pYM/MDRl (0) or pYM/MDR2 (A). The as- 
say was done in triplicate as described in Section 2. The values are 
expressed relative to each transformant strain grown in the absence 
of the drug. B: Relative resistance of W303-lAY18 harboring the 
control vector, pYM/MDRl or pYMIMDR2. Relative resistance 
was calculated by comparing the ICsos. The results are presented 
relative to W303-lAY18 harboring the control vector. Each bar rep- 
resents the average of three experiments. 
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plasma membrane of human cells and that aureobasidin A 
binds to the common drug binding site(s). 
Next we examined these MDR modulators for resistance to 
aureobasidin A conferred by MDR2/Pgp, and found that the 
inhibitory effects of these MDR modulators were almost iden- 
tical to the effect on the resistance conferred by MDRl/Pgp 
(Fig. SB). These results strongly suggest that human MDR21 
Pgp has the conserved domain(s) for drug recognition in com- 
mon with the MDRl/Pgp. 
It has been suggested that the physiological roles and the 
substrate specificity of MDRl/Pgp and MDR21Pgp are differ- 
ent. But MDR2/Pgp shares about 80% identity at the amino 
acid level with MDRlIPgp. Several groups have identified the 
mutations to amino acids that modulate the substrate speci- 
ficity of human and mouse Pgps, which are in the 4th, 6th, 
8th, lOth, 1 lth, and 12th transmembrane domains and the lst, 
2nd, and 4th cytoplasmic loops [24-261. However, all the re- 
ported amino acids were conserved between MDRl and 
MDR2IPgps. Recently it was reported that the mouse mdr21 
Pgp-mediated phosphatidylcholine translocation was inhibited 
by verapamil [9], suggesting that binding sites for verapamil, 
which is known as a Pgp inhibitor but is also a substrate for 
MDRllPgp to transport ([27], our unpublished results), are 
conserved between MDRllPgp and MDR21Pgp. These results 
have suggested that a part of the mechanism of drug binding 
by MDR2/Pgp overlaps with that of MDRUPgp. In this pa- 
per, we reported that MDR2/Pgp expressed in yeast cells re- 
tains an ability to interact with a variety of typical MDRl 
substrates. Nevertheless, overexpression of human MDR2/ 
Pgp or mouse mdr2/Pgp cannot confer multidrug resistance 
on drug-sensitive mammalian cells, which has been confirmed 
by several groups [4,5]. We have reported [7] that human 
MDRl/Pgp transports cortisol, aldosterone, and dexametha- 
sone, but not progesterone, although progesterone directly 
binds MDRl/Pgp, inhibits azidopine photoaffinity labeling 
of MDRlIPgp, and increases the sensitivity of multidrug-re- 
sistant cells to vinblastine. These results suggest that sub- 
stances that efficiently bind to Pgp are not necessarily trans- 
ported by Pgp. 
In this paper we showed for the first time that human 
1 10 100 
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Fig. 4. A: Effects of aureobasidin A on the growth of human MDR 
cultured cells KB-G2 (0, ??) and drug-sensitive KB-3-1 cells (a, 
A). Growth inhibition was analyzed in the absence (0, A) or pres- 
ence (0, A ) of 2 ug/ml aureobasidin A by MTT assay as previously 
described [7]. B: Azidopine photolabeling of P-glycoprotein. 10 pg 
of membrane protein from human MDR cultured cells KB-G2 was 
photolabeled with 0.2 uM [3H]azidopine in the absence (lane 1) or 
presence of 5 pM (a 25-fold excess) (lane 2), 10 uM (a 50-fold ex- 
cess) (lane 3), 20 pM (a loo-fold excess) (lane 4) of aureobasidin A 
as previously described [7]. P-glycoprotein is indicated by an arrow 
on the right. 
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Fig. 5. Effects of MDR modulators on aureobasidin A resistance of 
W303-lAY18 harboring pYM/MDRl (A) or pYM/MDR2 (B). 
Growth inhibition assay was done in the absence (-) or in the pres- 
ence of verapamil (50, 100, and 200 uM), vinblastine (5, 50, 100, 
and 200 PM), cyclosporin A (1, 5, 25, and 50 FM), or colchicine 
(200 PM) as described in Section 2. The results are presented rela- 
tive to W303-lAY18 harboring the control vector. MDR modula- 
tors of these concentrations have no effect on the growth of W303- 
lAY18. Each bar represents the average of at least three experi- 
ments. 
MDRl and MDR21Pgps would recognize a common sub- 
strate. Because MDR2/Pgp is considered to interact with 
phosphatidylcholine in the inner leaflet of the lipid bilayer 
and to translocate it to the outer leaflet, it is conceivable 
that MDRl/Pgp also removes some of its substrates from 
the inner leaflet of the plasma membrane. These results will 
promote the understanding of the mechanisms of drug recog- 
nition and transport and the physiological functions of the 
human MDRl and MDR2/Pgps. 
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